Live Analyst Rating Changes 24314 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Julien Dormois
JEF

Julien Dormois

Jefferies
Wall Street Analyst
★★★☆☆
#2082
on 13Foresight · ranked by our own returns
47%
Success Rate
+0.4%
Average Return
9 of 19 calls profitable · -8.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 47% of Julien Dormois's ratings turned a profit when each position was held for 1 year — averaging +0.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 17 Hold 0 Sell
Julien's Stock Coverage 14 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GB:CTEC
ConvaTec
 Aug 05, 2026 BUY Strong Buy
+27.1% avg upside
18 analysts
$300.00
28.61% Upside
 +0.0% ·
IT:AMP
Amplifon S.p.A.
 Aug 04, 2026 HOLD Buy
+96.2% avg upside
13 analysts
$12.50
2.08% Upside
 -0.5% ·
DE:SHL
Siemens Healthineers AG
 Jul 31, 2026 BUY Buy
+25.8% avg upside
24 analysts
$50.00
28.09% Upside
 -0.0% ·
FR:EL
EssilorLuxottica SA
 Jul 28, 2026 BUY Strong Buy
+10.2% avg upside
17 analysts
$250.00
52.16% Upside
 +3.8% ·
NL:PHIA
Koninklijke Philips N.V.
 Jul 07, 2026 HOLD Buy
+30.7% avg upside
21 analysts
$25.00
7.76% Upside
 -4.7% ·
GB:0K9P
GN Store Nord
 Mar 18, 2026 HOLD Hold
+140.0% avg upside
13 analysts
$111.00
11.18% Upside
 · ·
CH:STMN
Straumann Holding AG
 Feb 19, 2026 HOLD Buy
+23.1% avg upside
15 analysts
$110.00
6.97% Upside
 +9.8% ·
CH:SOON
Sonova Holding AG
 Sep 30, 2025 HOLD Hold
-6.8% avg upside
18 analysts
$235.00
2.10% Downside
 +10.7% ·
GB:0QBO
Coloplast A/S
 Aug 20, 2025 BUY Buy
+67.8% avg upside
17 analysts
$800.00
82.94% Upside
 · ·
GB:SN
Smith & Nephew
 Aug 06, 2025 BUY Buy
+1245.9% avg upside
16 analysts
$1500.00
37.08% Upside
 -18.3% ·
WILLF
Demant
 Feb 06, 2025 HOLD Buy
-6.0% avg upside
19 analysts
$40.90
8.92% Downside
 -6.3% ·
PHG
Koninklijke Philips
 Nov 29, 2024 HOLD Buy
+35.1% avg upside
13 analysts
$26.40
1.50% Downside
 +7.5% ·
SE:EKTA.B
Elekta AB
 Nov 30, 2023 HOLD Strong Sell
+15.1% avg upside
12 analysts
$85.00
62.52% Upside
 -18.0% ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 Jun 05, 2020 BUY Hold
+21.8% avg upside
23 analysts
 — -8.9% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Julien Dormois — Frequently Asked Questions
How accurate are Julien Dormois's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Julien's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, or -8.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Julien ranked on 13Foresight?
Julien Dormois is currently ranked #2082 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Julien cover?
Julien most recently has ratings on GB:CTEC, IT:AMP, DE:SHL, FR:EL, NL:PHIA, GB:0K9P, CH:STMN, CH:SOON, GB:0QBO, GB:SN, WILLF, PHG and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.